Abstract
Ninety-five unselected patients with stage III and IV T cell lymphoblastic lymphoma were treated according to the United Kingdom Children's Cancer Study Group protocol 8503. This was a continuous, intensive leukaemia type regimen including cranial irradiation (18 Gy in 10 fractions) and continuing chemotherapy for 2 years identical to the concurrent Medical Research Council ALL protocol. Four-year event-free survival was 65% (95% CI 50-80%) with no significant difference between stage III and stage IV cases. 4.2% of patients died of infection or non-tumour related events. Following relapse salvage was unlikely without high dose chemotherapy and bone marrow rescue. These results show an improvement over previous U.K. studies but we need to continue to search for subsets of patients with resistant disease for whom even more intensive therapy possibly combined with bone marrow rescue is required.
Publication types
-
Clinical Trial
-
Multicenter Study
MeSH terms
-
Adolescent
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Asparaginase / administration & dosage
-
Bone Marrow Transplantation
-
Child
-
Child, Preschool
-
Combined Modality Therapy
-
Daunorubicin / administration & dosage
-
Humans
-
Infant
-
Mercaptopurine / administration & dosage
-
Methotrexate / administration & dosage
-
Neoplasm Staging
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy*
-
Prednisolone / administration & dosage
-
Time Factors
-
Trimethoprim, Sulfamethoxazole Drug Combination / administration & dosage
-
Vincristine / administration & dosage
Substances
-
Vincristine
-
Trimethoprim, Sulfamethoxazole Drug Combination
-
Prednisolone
-
Mercaptopurine
-
Asparaginase
-
Methotrexate
-
Daunorubicin
Supplementary concepts
-
non-Hodgkin's lymphoma protocol 8503